Moderna Says Its COVID-19 Vaccine Showed 96 Per Cent Efficacy In Study On Adolescents Aged Between 12-17 Years

United States (US)-based pharmaceutical major and vaccine maker Moderna has said that the studies of its two-dose mRNA COVID-19 vaccine in teenagers has shown an efficacy rate of 96 per cent, reports Hindustan Times.

The study was conducted among adolescent participants from the age group of 12-17 years. The company claims that the vaccine has shown no serious safety problems and that it will ll build up its production capacity to boost the supplies of its vaccine.

The company has also recently released the results of preliminary human trials showing that two types of booster shots of its vaccine helped bolster immune responses against variants that surfaced in South Africa and Brazil.

The company had recently announced investments in its US plants and overseas contractors to raise the production to as much as three billion doses next year.

Moderna Inc's vaccine is already being widely used in the US for inoculation of American adults against COVID-19.